Index RUT P/E - EPS (ttm) -3.41 Insider Own 16.33% Shs Outstand 69.43M Perf Week 2.71%
Market Cap 1.95B Forward P/E - EPS next Y -3.81 Insider Trans -3.17% Shs Float 58.09M Perf Month 6.57%
Income -204.18M PEG - EPS next Q -0.88 Inst Own 98.53% Short Float 12.24% Perf Quarter 21.03%
Sales 0.00M P/S - EPS this Y -24.85% Inst Trans 15.46% Short Ratio 11.04 Perf Half Y 8.25%
Book/sh 11.53 P/B 2.44 EPS next Y -5.57% ROA -26.71% Short Interest 7.11M Perf Year -42.22%
Cash/sh 10.95 P/C 2.56 EPS next 5Y - ROE -28.87% 52W Range 11.25 - 51.81 Perf YTD 20.26%
Dividend Est. - P/FCF - EPS past 5Y 1.03% ROI -24.49% 52W High -45.80% Beta -0.26
Dividend TTM - Quick Ratio 24.89 Sales past 5Y 0.00% Gross Margin - 52W Low 149.60% ATR (14) 1.29
Dividend Ex-Date - Current Ratio 24.89 EPS Y/Y TTM -33.20% Oper. Margin 0.00% RSI (14) 62.15 Volatility 4.53% 4.66%
Employees 56 Debt/Eq 0.05 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 48.62
Option/Short Yes / Yes LT Debt/Eq 0.04 EPS Q/Q -35.07% Payout - Rel Volume 2.38 Prev Close 28.00
Sales Surprise - EPS Surprise 2.37% Sales Q/Q - Earnings Aug 09 BMO Avg Volume 643.93K Price 28.08
SMA20 5.55% SMA50 7.03% SMA200 19.76% Trades
Volume 1,529,464 Change 0.29%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-24 Resumed BofA Securities
Neutral
$30
Sep-19-23 Initiated Cantor Fitzgerald
Overweight
$69
Aug-28-23 Initiated UBS
Buy
$83
Jan-27-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$40 → $65
Sep-14-22 Upgrade Evercore ISI
In-line → Outperform
$10 → $50
Oct-19-21 Downgrade Morgan Stanley
Overweight → Equal-Weight
$27
Sep-10-21 Initiated BofA Securities
Buy
$40
Feb-26-21 Initiated Guggenheim
Buy
$54
Sep-10-20 Initiated Morgan Stanley
Overweight
$70
Jul-20-20 Reiterated H.C. Wainwright
Buy
$45 → $62
Jul-07-20 Initiated Chardan Capital Markets
Buy
$79
Jul-01-20 Reiterated H.C. Wainwright
Buy
$33 → $45
Mar-02-20 Initiated H.C. Wainwright
Buy
$33
Feb-10-20 Initiated Canaccord Genuity
Buy
$36
Jul-15-19 Initiated ROTH Capital
Buy
$34
Jul-15-19 Initiated JP Morgan
Overweight
$28
Jul-15-19 Initiated Jefferies
Buy
$28
Jul-15-19 Initiated Evercore ISI
Outperform
$35
Show Previous Ratings
Sep-12-24 01:12AM
Sep-09-24 07:00AM
Sep-05-24 12:02AM
Sep-02-24 05:22PM
Aug-28-24 04:05PM
02:53PM
Loading…
Aug-09-24 02:53PM
07:00AM
Jul-16-24 12:00PM
Jun-28-24 10:40AM
Jun-24-24 01:04PM
Jun-21-24 11:06AM
Jun-19-24 02:45PM
Jun-17-24 10:23AM
Jun-13-24 03:57PM
09:00AM
07:00AM
Loading…
Jun-11-24 07:00AM
Jun-10-24 10:14AM
Jun-08-24 08:15AM
Jun-06-24 10:39AM
Jun-03-24 09:57AM
May-30-24 09:16PM
May-29-24 07:00AM
May-23-24 02:12PM
May-15-24 09:26AM
May-12-24 09:01PM
May-10-24 01:54PM
07:45AM
07:00AM
May-08-24 07:00AM
Apr-30-24 08:00AM
06:00AM
Loading…
Apr-22-24 06:00AM
Mar-20-24 01:32PM
12:58PM
Mar-18-24 07:00AM
(The Wall Street Journal)
Mar-08-24 04:02PM
Mar-07-24 04:01PM
Mar-06-24 11:54PM
Mar-05-24 09:13PM
02:12PM
Mar-04-24 04:21PM
04:04PM
(Investor's Business Daily)
12:30PM
(The Wall Street Journal)
11:59AM
09:23AM
(Investor's Business Daily)
06:22AM
06:09AM
06:00AM
04:00AM
Mar-01-24 09:55AM
Feb-29-24 08:00AM
07:00AM
Feb-06-24 10:48AM
Feb-05-24 09:55AM
Jan-30-24 09:40AM
Jan-03-24 08:15AM
Dec-18-23 07:00AM
Dec-13-23 03:06AM
Dec-05-23 01:34PM
12:36PM
Nov-14-23 07:21PM
Nov-13-23 07:00AM
Nov-10-23 08:57AM
Nov-08-23 07:00AM
Oct-17-23 04:05PM
Oct-12-23 04:38PM
08:24AM
Oct-11-23 05:35PM
11:11AM
Oct-10-23 04:13PM
04:03PM
(Investor's Business Daily)
12:10PM
(Associated Press Finance)
11:44AM
10:37AM
09:29AM
07:15AM
07:00AM
Oct-09-23 04:05PM
Oct-05-23 07:01AM
Oct-04-23 08:00AM
Sep-29-23 12:43PM
Sep-27-23 09:24PM
Sep-14-23 07:56AM
Aug-31-23 07:00AM
Aug-28-23 07:00AM
Aug-11-23 06:00AM
Jul-11-23 09:02AM
Jul-10-23 09:32AM
09:29AM
08:58AM
Jul-07-23 08:00AM
(The Wall Street Journal)
07:46AM
Jul-03-23 11:20AM
10:25AM
Jul-01-23 09:00AM
Jun-29-23 10:04AM
09:59AM
09:18AM
Jun-28-23 10:53AM
Jun-27-23 01:47PM
Jun-26-23 11:23AM
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Yale Catriona Chief Development Officer Sep 18 '24 Option Exercise 0.61 3,871 2,381 79,165 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 16 '24 Option Exercise 0.61 2,485 1,528 77,779 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 17 '24 Option Exercise 0.61 2,037 1,253 77,331 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 18 '24 Sale 27.56 3,871 106,685 75,294 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 16 '24 Sale 27.52 2,485 68,375 75,294 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 17 '24 Sale 27.55 2,037 56,115 75,294 Sep 18 09:19 PM CATRIONA YALE Officer Sep 16 '24 Proposed Sale 27.34 13,893 379,835 Sep 16 04:34 PM Young Jonathan Chief Operating Officer Sep 10 '24 Sale 26.18 568 14,870 236,286 Sep 13 05:16 PM Yale Catriona Chief Development Officer Sep 10 '24 Sale 26.18 637 16,677 75,294 Sep 13 05:14 PM White William Richard Chief Financial Officer Sep 10 '24 Sale 26.18 639 16,729 41,152 Sep 13 05:13 PM Rolph Timothy Chief Scientific Officer Sep 10 '24 Sale 26.18 537 14,059 180,705 Sep 13 05:11 PM Cheng Andrew President and CEO Sep 10 '24 Sale 26.18 1,738 45,501 605,417 Sep 13 05:10 PM Young Jonathan Chief Operating Officer Sep 03 '24 Sale 26.72 5,000 133,588 236,854 Sep 05 04:08 PM Yale Catriona Chief Development Officer Sep 03 '24 Option Exercise 0.61 949 584 76,880 Sep 05 04:05 PM Yale Catriona Chief Development Officer Sep 03 '24 Sale 27.61 949 26,206 75,931 Sep 05 04:05 PM White William Richard Chief Financial Officer Aug 26 '24 Option Exercise 14.57 75,159 1,095,329 74,462 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 27 '24 Option Exercise 21.09 23,175 488,761 64,966 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 26 '24 Sale 27.21 75,159 2,045,152 41,791 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 27 '24 Sale 26.41 23,175 612,098 41,791 Aug 29 04:30 PM Yale Catriona Chief Development Officer Aug 23 '24 Option Exercise 0.61 8,851 5,443 84,782 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 26 '24 Option Exercise 0.61 5,200 3,198 81,131 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 23 '24 Sale 27.53 8,851 243,641 75,931 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 26 '24 Sale 27.51 5,200 143,073 75,931 Aug 28 11:11 AM White William Richard Officer Aug 26 '24 Proposed Sale 27.46 98,334 2,700,252 Aug 26 04:32 PM CATRIONA YALE Officer Aug 23 '24 Proposed Sale 26.11 15,000 391,650 Aug 23 04:27 PM Cheng Andrew President and CEO Aug 16 '24 Option Exercise 0.61 24,538 15,091 607,155 Aug 20 11:45 AM Young Jonathan Chief Operating Officer Aug 01 '24 Sale 26.75 5,000 133,756 241,854 Aug 02 09:32 PM White William Richard Chief Financial Officer Jul 24 '24 Option Exercise 7.01 139,083 974,833 180,874 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 25 '24 Option Exercise 7.01 22,272 156,104 64,063 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 23 '24 Option Exercise 7.01 500 3,504 42,291 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 24 '24 Sale 26.98 139,083 3,753,041 41,791 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 25 '24 Sale 27.61 22,272 614,820 41,791 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 23 '24 Sale 28.01 500 14,005 41,791 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 16 '24 Option Exercise 7.01 29,803 208,889 76,602 Jul 18 09:41 PM White William Richard Chief Financial Officer Jul 16 '24 Sale 28.04 34,811 976,274 41,791 Jul 18 09:41 PM Young Jonathan Chief Operating Officer Jul 01 '24 Sale 23.40 5,000 117,020 246,854 Jul 02 06:55 PM Young Jonathan Chief Operating Officer Jun 11 '24 Sale 22.64 2,516 56,965 250,790 Jun 13 06:13 PM Yale Catriona Chief Development Officer Jun 11 '24 Sale 22.64 2,825 63,961 74,867 Jun 13 06:11 PM White William Richard Chief Financial Officer Jun 11 '24 Sale 22.64 2,831 64,094 46,799 Jun 13 06:09 PM Rolph Timothy Chief Scientific Officer Jun 11 '24 Sale 22.64 2,380 53,886 180,178 Jun 13 06:06 PM Lamy Patrick Senior VP, Commercial Strategy Jun 11 '24 Sale 22.64 569 12,883 18,562 Jun 13 06:04 PM Cheng Andrew President and CEO Jun 11 '24 Sale 22.64 7,894 178,728 581,553 Jun 13 06:01 PM Young Jonathan Chief Operating Officer Jun 03 '24 Sale 19.29 5,000 96,440 253,306 Jun 05 05:05 PM Young Jonathan Chief Operating Officer May 01 '24 Sale 20.15 5,000 100,750 258,306 May 02 09:07 PM Young Jonathan Chief Operating Officer Apr 01 '24 Sale 24.38 5,000 121,913 263,306 Apr 03 06:55 PM Yale Catriona Chief Development Officer Mar 13 '24 Sale 28.33 723 20,483 77,692 Mar 15 04:45 PM White William Richard Chief Financial Officer Mar 13 '24 Sale 28.33 724 20,511 49,630 Mar 15 04:44 PM Cheng Andrew President and CEO Mar 13 '24 Sale 28.33 1,969 55,782 589,447 Mar 15 04:43 PM Young Jonathan Chief Operating Officer Mar 13 '24 Sale 28.33 651 18,443 268,306 Mar 15 04:42 PM Rolph Timothy Chief Scientific Officer Mar 13 '24 Sale 28.33 619 17,536 182,558 Mar 15 04:42 PM Cheng Andrew President and CEO Mar 04 '24 Option Exercise 17.17 75,000 1,288,062 666,416 Mar 06 08:14 PM Cheng Andrew President and CEO Mar 04 '24 Sale 32.87 75,000 2,465,063 591,416 Mar 06 08:14 PM Yale Catriona Chief Development Officer Mar 04 '24 Option Exercise 13.96 20,646 288,124 99,061 Mar 06 08:13 PM Yale Catriona Chief Development Officer Mar 04 '24 Sale 35.49 20,646 732,727 78,415 Mar 06 08:13 PM Young Jonathan Chief Operating Officer Mar 01 '24 Option Exercise 0.61 83,321 51,242 268,957 Mar 05 05:16 PM Cheng Andrew President and CEO Jan 02 '24 Option Exercise 0.61 40,000 24,600 590,911 Jan 03 05:00 PM Young Jonathan Chief Operating Officer Dec 27 '23 Option Exercise 6.36 5,414 34,433 190,545 Dec 29 08:30 PM Young Jonathan Chief Operating Officer Dec 27 '23 Sale 24.00 5,414 129,936 185,131 Dec 29 08:30 PM Yale Catriona Chief Development Officer Dec 14 '23 Sale 20.76 597 12,394 77,910 Dec 18 08:49 PM White William Richard Chief Financial Officer Dec 14 '23 Sale 20.76 611 12,684 50,354 Dec 18 08:40 PM Young Jonathan Chief Operating Officer Dec 14 '23 Sale 20.76 543 11,273 185,131 Dec 18 08:39 PM Cheng Andrew President and CEO Dec 14 '23 Sale 20.76 1,628 33,797 550,911 Dec 18 08:37 PM Rolph Timothy Chief Scientific Officer Dec 14 '23 Sale 20.76 514 10,671 182,672 Dec 18 08:29 PM Graham G. Walmsley Director Dec 08 '23 Buy 19.83 100,000 1,982,940 800,000 Dec 11 09:06 PM Cheng Andrew President and CEO Dec 08 '23 Option Exercise 6.36 12,873 81,872 473,871 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 11 '23 Option Exercise 6.36 7,405 47,096 559,944 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 07 '23 Option Exercise 6.36 6,700 42,612 467,698 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 08 '23 Sale 20.01 12,873 257,571 460,998 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 11 '23 Sale 20.02 7,405 148,273 552,539 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 07 '23 Sale 20.02 6,700 134,125 460,998 Dec 11 08:59 PM Graham G. Walmsley Director Dec 01 '23 Buy 16.99 50,000 849,730 700,000 Dec 05 08:37 AM Graham G. Walmsley Director Nov 30 '23 Buy 16.90 50,000 844,835 650,000 Dec 05 08:37 AM Young Jonathan Chief Operating Officer Nov 17 '23 Sale 14.68 30,000 440,259 153,177 Nov 21 05:30 PM Cheng Andrew President and CEO Oct 02 '23 Option Exercise 6.36 25,000 159,000 485,998 Oct 04 08:41 PM Cheng Andrew President and CEO Oct 02 '23 Sale 47.91 25,000 1,197,827 460,998 Oct 04 08:41 PM Young Jonathan Chief Operating Officer Oct 02 '23 Option Exercise 21.10 490 10,339 183,667 Oct 04 08:33 PM Young Jonathan Chief Operating Officer Oct 02 '23 Sale 51.10 490 25,039 183,177 Oct 04 08:33 PM Yale Catriona Chief Development Officer Sep 21 '23 Option Exercise 6.36 5,000 31,800 51,010 Sep 25 08:31 PM Yale Catriona Chief Development Officer Sep 21 '23 Sale 48.07 5,000 240,356 46,010 Sep 25 08:31 PM
Index RUT P/E - EPS (ttm) -3.66 Insider Own 47.78% Shs Outstand 24.36M Perf Week 0.67%
Market Cap 1.43B Forward P/E - EPS next Y -5.01 Insider Trans 2.74% Shs Float 15.52M Perf Month -2.43%
Income -91.00M PEG - EPS next Q -1.06 Inst Own 58.46% Short Float 9.56% Perf Quarter 8.90%
Sales 0.00M P/S - EPS this Y -30.53% Inst Trans 3.39% Short Ratio 5.64 Perf Half Y -21.66%
Book/sh 13.69 P/B 3.51 EPS next Y -12.14% ROA -20.35% Short Interest 1.48M Perf Year -1.78%
Cash/sh 16.85 P/C 2.86 EPS next 5Y - ROE -21.16% 52W Range 25.60 - 77.60 Perf YTD -16.71%
Dividend Est. - P/FCF - EPS past 5Y - ROI -26.82% 52W High -38.00% Beta 0.59
Dividend TTM - Quick Ratio 23.70 Sales past 5Y 0.00% Gross Margin - 52W Low 87.93% ATR (14) 2.03
Dividend Ex-Date - Current Ratio 25.02 EPS Y/Y TTM 6.61% Oper. Margin 0.00% RSI (14) 49.95 Volatility 3.82% 4.14%
Employees 74 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.30 Target Price 66.10
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -38.43% Payout - Rel Volume 3.81 Prev Close 48.58
Sales Surprise - EPS Surprise 6.74% Sales Q/Q - Earnings Aug 08 BMO Avg Volume 263.21K Price 48.11
SMA20 -2.11% SMA50 2.45% SMA200 -2.52% Trades
Volume 1,003,797 Change -0.97%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-22-24 Initiated Wells Fargo
Overweight
$75
Apr-01-24 Downgrade Raymond James
Strong Buy → Outperform
$40
Dec-19-23 Downgrade Morgan Stanley
Overweight → Equal-Weight
$56 → $65
Jun-09-23 Upgrade Raymond James
Outperform → Strong Buy
$50 → $75
Jun-07-23 Initiated H.C. Wainwright
Buy
$55
May-17-23 Initiated Raymond James
Outperform
$50
Apr-28-23 Initiated Cantor Fitzgerald
Overweight
$45
Apr-21-23 Initiated Stifel
Buy
$37
Apr-20-23 Initiated Morgan Stanley
Overweight
$37
Mar-23-23 Initiated BMO Capital Markets
Outperform
$40
Feb-28-23 Initiated SVB Securities
Outperform
$36
Show Previous Ratings
Sep-19-24 08:30AM
08:30AM
Aug-30-24 08:00AM
Aug-08-24 08:00AM
Jun-28-24 08:11PM
08:03AM
Loading…
Jun-14-24 08:03AM
07:30AM
May-30-24 09:00AM
May-14-24 10:30AM
May-13-24 08:00AM
May-11-24 05:31AM
May-09-24 01:54PM
08:00AM
Apr-02-24 02:24PM
Apr-01-24 04:19PM
(Investor's Business Daily) -45.05%
08:00AM
Loading…
08:00AM
Mar-23-24 05:31AM
Mar-21-24 08:00AM
Mar-06-24 04:30PM
Feb-26-24 08:30AM
Feb-20-24 08:30AM
Feb-09-24 09:00AM
Feb-07-24 08:00AM
Jan-03-24 05:00PM
Dec-22-23 06:35PM
Dec-20-23 04:30PM
Dec-15-23 03:01PM
Dec-11-23 08:30PM
12:00PM
Dec-08-23 07:06AM
04:44PM
Loading…
Nov-14-23 04:44PM
Nov-13-23 09:55AM
Nov-09-23 09:34AM
08:30AM
Nov-08-23 04:30PM
Nov-02-23 09:00AM
Oct-23-23 09:15AM
Oct-03-23 08:30AM
Sep-20-23 04:30PM
Aug-30-23 04:15PM
Aug-24-23 11:20AM
(Investor's Business Daily)
Aug-11-23 08:50AM
08:00AM
Jul-27-23 09:00AM
Jul-25-23 09:55AM
Jun-22-23 04:15PM
Jun-20-23 07:33PM
Jun-13-23 10:39PM
Jun-12-23 04:00PM
01:59AM
Jun-09-23 04:13PM
(Investor's Business Daily) +15.76%
07:00AM
Jun-01-23 03:10PM
May-31-23 04:00PM
May-15-23 07:00AM
May-11-23 10:15AM
May-10-23 10:23AM
May-05-23 08:50AM
May-04-23 12:00PM
Apr-28-23 05:00AM
Apr-27-23 08:05AM
Apr-21-23 08:30AM
Apr-19-23 08:50AM
Apr-13-23 11:00AM
Mar-31-23 07:00AM
Mar-30-23 07:05AM
Mar-21-23 07:00AM
Feb-16-23 08:00AM
Feb-14-23 06:30AM
Feb-08-23 04:00PM
Jan-20-23 07:00AM
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company was founded in October 2017 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Savage William Jacob Chief Medical Officer Sep 16 '24 Sale 47.41 1,500 71,115 40,405 Sep 18 04:05 PM WILLIAM SAVAGE Officer Sep 16 '24 Proposed Sale 47.79 1,500 71,685 Sep 16 04:39 PM White William Richard Director Sep 03 '24 Option Exercise 3.39 1,957 6,635 1,957 Sep 05 04:06 PM White William Richard Director Sep 03 '24 Sale 49.65 1,957 97,158 0 Sep 05 04:06 PM Savage William Jacob Chief Medical Officer Sep 03 '24 Sale 50.59 1,500 75,885 41,905 Sep 04 04:05 PM WILLIAM SAVAGE Officer Sep 03 '24 Proposed Sale 50.82 1,500 76,230 Sep 03 04:15 PM White William Richard Director Aug 01 '24 Option Exercise 9.86 201 1,982 201 Aug 05 04:15 PM White William Richard Director Aug 01 '24 Sale 43.44 201 8,731 0 Aug 05 04:15 PM White William Richard Director Aug 01 '24 Proposed Sale 43.16 9,696 418,479 Aug 01 05:10 PM Quisel John D Chief Executive Officer Jul 08 '24 Option Exercise 1.01 3,000 3,030 72,065 Jul 10 04:15 PM White William Richard Director Jul 01 '24 Option Exercise 9.86 201 1,982 201 Jul 03 04:15 PM White William Richard Director Jul 01 '24 Sale 46.04 201 9,253 0 Jul 03 04:15 PM Bitterman Kevin Director Jun 17 '24 Buy 36.00 222,223 8,000,028 420,549 Jun 20 08:00 PM Ashiya Mona Director Jun 17 '24 Buy 36.00 83,334 3,000,024 941,569 Jun 20 05:27 PM ORBIMED ADVISORS LLC Director Jun 17 '24 Buy 36.00 83,334 3,000,024 941,569 Jun 20 05:19 PM White William Richard Director Jun 03 '24 Option Exercise 3.39 1,957 6,635 1,957 Jun 05 04:05 PM White William Richard Director Jun 03 '24 Sale 36.08 1,957 70,608 0 Jun 05 04:05 PM White William Richard Director May 01 '24 Option Exercise 9.86 201 1,982 201 May 03 04:05 PM White William Richard Director May 01 '24 Sale 28.63 201 5,755 0 May 03 04:05 PM White William Richard Director Apr 11 '24 Option Exercise 4.91 2,560 12,581 2,560 Apr 15 06:27 PM White William Richard Director Apr 11 '24 Sale 31.80 2,560 81,407 0 Apr 15 06:27 PM Savage William Jacob Chief Medical Officer Apr 10 '24 Option Exercise 2.65 21,870 57,956 43,405 Apr 11 05:02 PM Bitterman Kevin Director Mar 05 '24 Sale 73.50 26,157 1,922,540 677,503 Mar 07 04:40 PM Bitterman Kevin Director Jan 23 '24 Sale 67.65 102,500 6,934,125 198,326 Jan 25 04:33 PM Atlas Venture Fund X, L.P. 10% Owner Jan 23 '24 Sale 67.65 102,500 6,934,125 198,326 Jan 25 04:31 PM Atlas Venture Fund X, L.P. 10% Owner Jan 23 '24 Sale 67.65 47,500 3,213,375 1,402,186 Jan 25 04:31 PM Bitterman Kevin Director Jan 10 '24 Sale 64.00 20,000 1,280,000 786,160 Jan 12 05:12 PM Atlas Venture Fund X, L.P. 10% Owner Jan 10 '24 Sale 64.00 30,000 1,920,000 1,449,686 Jan 12 05:12 PM Atlas Venture Fund X, L.P. 10% Owner Jan 10 '24 Sale 64.00 20,000 1,280,000 786,160 Jan 12 05:12 PM Quisel John D Chief Executive Officer Dec 29 '23 Option Exercise 1.01 2,700 2,727 2,700 Jan 03 04:05 PM Bryce Joanne Chief Financial Officer Dec 27 '23 Option Exercise 9.86 3,000 29,580 5,500 Dec 29 04:15 PM ORBIMED ADVISORS LLC Director Dec 18 '23 Option Exercise 38.00 1,724 65,512 1,724 Dec 20 06:28 PM ORBIMED ADVISORS LLC Director Dec 18 '23 Sale 59.24 1,724 102,130 0 Dec 20 06:28 PM Ashiya Mona Director Dec 18 '23 Option Exercise 38.00 1,724 65,512 1,724 Dec 20 06:16 PM Ashiya Mona Director Dec 18 '23 Sale 59.24 1,724 102,130 0 Dec 20 06:16 PM Ashiya Mona Director Dec 14 '23 Sale 56.75 433,200 24,584,100 224,405 Dec 15 06:09 PM ORBIMED ADVISORS LLC Director Dec 14 '23 Sale 56.75 433,200 24,584,100 224,405 Dec 15 06:04 PM Bitterman Kevin Director Dec 12 '23 Sale 62.80 51,967 3,263,328 830,257 Dec 14 08:14 PM Bitterman Kevin Director Dec 14 '23 Sale 58.28 20,549 1,197,567 806,160 Dec 14 08:14 PM Bitterman Kevin Director Dec 13 '23 Sale 60.00 3,548 212,865 826,709 Dec 14 08:14 PM Atlas Venture Fund X, L.P. 10% Owner Dec 12 '23 Sale 62.80 77,951 4,895,032 1,515,834 Dec 14 08:13 PM Atlas Venture Fund X, L.P. 10% Owner Dec 12 '23 Sale 62.80 51,967 3,263,328 830,257 Dec 14 08:13 PM Atlas Venture Fund X, L.P. 10% Owner Dec 14 '23 Sale 58.28 30,825 1,796,437 1,479,686 Dec 14 08:13 PM Atlas Venture Fund X, L.P. 10% Owner Dec 14 '23 Sale 58.28 20,549 1,197,567 806,160 Dec 14 08:13 PM Atlas Venture Fund X, L.P. 10% Owner Dec 13 '23 Sale 60.00 5,323 319,357 1,510,511 Dec 14 08:13 PM Atlas Venture Fund X, L.P. 10% Owner Dec 13 '23 Sale 60.00 3,548 212,865 826,709 Dec 14 08:13 PM ORBIMED ADVISORS LLC Director Dec 13 '23 Sale 58.56 106,700 6,248,352 281,505 Dec 14 05:44 PM ORBIMED ADVISORS LLC Director Dec 12 '23 Sale 60.16 27,300 1,642,368 295,605 Dec 14 05:44 PM ORBIMED ADVISORS LLC Director Dec 14 '23 Sale 57.73 200 11,546 727,807 Dec 14 05:44 PM Ashiya Mona Director Dec 13 '23 Sale 58.56 106,700 6,248,352 281,505 Dec 14 05:40 PM Ashiya Mona Director Dec 12 '23 Sale 60.16 27,300 1,642,368 295,605 Dec 14 05:40 PM Ashiya Mona Director Dec 14 '23 Sale 57.73 200 11,546 727,807 Dec 14 05:40 PM White William Richard Director Dec 12 '23 Option Exercise 6.08 33,511 203,883 33,511 Dec 14 04:15 PM White William Richard Director Dec 12 '23 Sale 63.21 33,511 2,118,239 0 Dec 14 04:15 PM Bryce Joanne Chief Financial Officer Dec 12 '23 Option Exercise 2.65 2,500 6,625 5,000 Dec 14 04:15 PM Bryce Joanne Chief Financial Officer Dec 12 '23 Sale 65.22 2,500 163,062 2,500 Dec 14 04:15 PM Bryce Joanne Chief Financial Officer Dec 05 '23 Option Exercise 1.01 1,281 1,294 5,041 Dec 07 04:15 PM Bryce Joanne Chief Financial Officer Dec 05 '23 Sale 56.00 2,541 142,299 2,500 Dec 07 04:15 PM Khara Rahul General Counsel Nov 22 '23 Option Exercise 14.69 10,000 146,900 10,000 Nov 27 04:15 PM Khara Rahul General Counsel Nov 22 '23 Sale 51.73 10,000 517,333 0 Nov 27 04:15 PM Khara Rahul General Counsel Nov 14 '23 Option Exercise 14.69 4,900 71,981 4,900 Nov 15 05:00 PM Khara Rahul General Counsel Nov 14 '23 Sale 50.61 4,900 248,012 0 Nov 15 05:00 PM Khara Rahul General Counsel Nov 03 '23 Option Exercise 14.69 100 1,469 100 Nov 07 06:22 PM Khara Rahul General Counsel Nov 03 '23 Sale 50.00 100 5,000 0 Nov 07 06:22 PM
Index RUT P/E - EPS (ttm) -2.79 Insider Own 22.62% Shs Outstand 59.24M Perf Week 0.44%
Market Cap 162.54M Forward P/E - EPS next Y -2.22 Insider Trans -0.06% Shs Float 54.69M Perf Month 17.35%
Income -171.30M PEG - EPS next Q -0.52 Inst Own 71.60% Short Float 15.65% Perf Quarter -8.37%
Sales 0.00M P/S - EPS this Y 34.66% Inst Trans 7.12% Short Ratio 8.29 Perf Half Y -68.71%
Book/sh 3.97 P/B 0.58 EPS next Y -3.01% ROA -52.07% Short Interest 8.56M Perf Year -93.57%
Cash/sh 3.39 P/C 0.68 EPS next 5Y - ROE -56.29% 52W Range 1.79 - 38.05 Perf YTD -6.88%
Dividend Est. - P/FCF - EPS past 5Y -148.81% ROI -58.85% 52W High -93.96% Beta 0.37
Dividend TTM - Quick Ratio 14.19 Sales past 5Y 0.00% Gross Margin - 52W Low 28.49% ATR (14) 0.15
Dividend Ex-Date - Current Ratio 14.19 EPS Y/Y TTM 0.34% Oper. Margin 0.00% RSI (14) 53.81 Volatility 6.03% 7.01%
Employees 80 Debt/Eq 0.04 Sales Y/Y TTM - Profit Margin - Recom 1.50 Target Price 11.29
Option/Short Yes / Yes LT Debt/Eq 0.04 EPS Q/Q 50.21% Payout - Rel Volume 0.74 Prev Close 2.37
Sales Surprise - EPS Surprise 22.25% Sales Q/Q - Earnings Aug 08 AMC Avg Volume 1.03M Price 2.30
SMA20 3.73% SMA50 0.15% SMA200 -35.60% Trades
Volume 759,538 Change -2.95%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-12-24 Upgrade Wells Fargo
Equal Weight → Overweight
$7 → $16
Mar-12-24 Upgrade Oppenheimer
Perform → Outperform
$12
Nov-07-23 Downgrade Wells Fargo
Overweight → Equal Weight
$77 → $8
Nov-07-23 Downgrade Stifel
Buy → Hold
$6
Nov-07-23 Downgrade Oppenheimer
Outperform → Perform
Nov-07-23 Downgrade Morgan Stanley
Overweight → Equal-Weight
$46 → $6
Nov-07-23 Downgrade H.C. Wainwright
Buy → Neutral
Jun-14-23 Resumed Credit Suisse
Outperform
$63
Mar-21-23 Initiated Wells Fargo
Overweight
$77
Dec-19-22 Initiated Goldman
Buy
$50
Nov-17-22 Initiated Morgan Stanley
Overweight
$45
Sep-07-22 Initiated Stifel
Buy
$45
Sep-01-22 Initiated H.C. Wainwright
Buy
$36
May-09-22 Initiated Credit Suisse
Outperform
$53
Mar-31-22 Initiated Canaccord Genuity
Buy
$30
Feb-01-22 Initiated Oppenheimer
Outperform
$30
Nov-15-21 Initiated Piper Sandler
Overweight
$50
Nov-15-21 Initiated Jefferies
Buy
$30
Show Previous Ratings
Sep-06-24 08:00AM
Aug-30-24 08:00AM
07:04AM
Aug-28-24 08:00AM
Aug-08-24 04:01PM
05:13PM
Loading…
Jul-30-24 05:13PM
(Pharmaceutical Technology)
Jul-29-24 08:00AM
08:00AM
Jun-05-24 04:01PM
(GlobeNewswire) +6.77%
-37.78%
May-16-24 04:05PM
(GlobeNewswire) +18.85%
-5.02%
11:23AM
08:00AM
May-13-24 09:02PM
10:37AM
May-09-24 08:59PM
04:01PM
Loading…
04:01PM
May-02-24 04:05PM
Apr-30-24 12:00PM
Apr-17-24 08:45AM
05:45AM
Apr-15-24 01:15PM
Mar-27-24 06:20AM
Mar-20-24 05:45AM
Mar-18-24 06:02PM
Mar-11-24 07:29AM
07:00AM
Mar-07-24 08:52AM
08:00AM
Mar-06-24 08:00AM
Mar-04-24 08:00AM
04:01PM
Loading…
Feb-27-24 04:01PM
Feb-22-24 07:00AM
Feb-21-24 04:09PM
Feb-06-24 04:05PM
Dec-23-23 11:01AM
Nov-21-23 04:05PM
Nov-10-23 08:00AM
Nov-09-23 04:01PM
09:35AM
Nov-07-23 04:20PM
(Investor's Business Daily) -80.62%
08:47AM
07:00AM
Nov-06-23 04:01PM
Nov-04-23 12:16PM
Oct-11-23 11:37AM
Oct-10-23 04:18PM
12:55PM
07:44AM
(The Wall Street Journal)
Oct-09-23 04:01PM
Oct-07-23 05:00AM
Oct-04-23 11:01PM
Sep-29-23 12:43PM
Sep-08-23 05:07PM
Aug-30-23 04:05PM
Aug-15-23 07:23AM
Aug-10-23 04:01PM
Aug-03-23 04:05PM
Aug-02-23 04:06PM
Jul-12-23 07:22AM
Jul-03-23 02:09PM
Jun-14-23 07:00AM
Jun-07-23 07:00AM
May-31-23 08:00AM
May-12-23 08:57AM
(Thomson Reuters StreetEvents) -7.11%
May-11-23 04:01PM
May-04-23 04:05PM
Mar-27-23 07:12AM
Mar-24-23 11:13AM
(Thomson Reuters StreetEvents) -5.23%
08:00AM
Mar-23-23 04:01PM
Mar-15-23 04:05PM
Mar-13-23 09:02AM
Mar-11-23 01:21PM
Feb-28-23 08:00AM
Feb-27-23 08:50AM
Feb-13-23 09:55AM
Feb-10-23 08:50AM
Feb-03-23 12:00PM
Jan-26-23 09:55AM
08:00AM
Jan-25-23 08:50AM
Jan-12-23 08:00AM
Jan-05-23 08:00AM
Jan-04-23 09:55AM
Dec-27-22 07:11AM
Dec-22-22 07:26AM
Dec-01-22 04:05PM
Nov-22-22 08:00AM
Nov-11-22 06:35PM
Nov-03-22 04:01PM
Oct-27-22 04:05PM
09:00AM
Oct-24-22 09:55AM
Sep-19-22 09:31AM
08:00AM
Sep-16-22 07:16PM
Sep-14-22 02:01PM
Aug-29-22 04:05PM
Aug-16-22 03:52PM
Aug-15-22 04:05PM
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mohan Raju CEO AND PRESIDENT Jun 10 '24 Option Exercise 0.20 96,778 19,356 1,675,028 Jun 11 04:47 PM Krueger Christopher W CHIEF BUSINESS OFFICER Apr 02 '24 Sale 5.40 1,651 8,921 284,999 Apr 03 07:37 PM Nuss John CHIEF SCIENTIFIC OFFICER Apr 02 '24 Sale 5.40 1,651 8,921 264,998 Apr 03 07:33 PM Mohan Raju CEO AND PRESIDENT Apr 02 '24 Sale 5.40 4,312 23,299 1,578,250 Apr 03 07:32 PM Auster Martin CHIEF FINANCIAL OFFICER Apr 02 '24 Sale 5.40 1,405 7,592 24,303 Apr 03 07:30 PM Krueger Christopher W CHIEF BUSINESS OFFICER Mar 28 '24 Option Exercise 0.00 4,531 0 286,650 Mar 29 06:15 PM Auster Martin CHIEF FINANCIAL OFFICER Mar 28 '24 Option Exercise 0.00 4,531 0 25,708 Mar 29 06:12 PM Mohan Raju CEO AND PRESIDENT Mar 28 '24 Option Exercise 0.00 11,843 0 1,582,562 Mar 29 06:09 PM Nuss John CHIEF SCIENTIFIC OFFICER Mar 28 '24 Option Exercise 0.00 4,531 0 266,649 Mar 29 06:07 PM Nuss John Chief Scientific Officer Dec 20 '23 Sale 2.12 17,628 37,334 262,118 Dec 21 08:14 PM Krueger Christopher W Chief Business Officer Dec 20 '23 Sale 2.12 5,293 11,210 282,119 Dec 21 08:12 PM Mohan Raju CEO and President Dec 20 '23 Sale 2.12 58,860 124,660 1,570,719 Dec 21 08:10 PM Mohan Raju CEO and President Dec 17 '23 Option Exercise 0.00 116,668 0 1,629,579 Dec 19 05:30 PM Nuss John Chief Scientific Officer Dec 17 '23 Option Exercise 0.00 34,931 0 279,746 Dec 19 05:27 PM Krueger Christopher W Chief Business Officer Dec 17 '23 Option Exercise 0.00 10,479 0 287,412 Dec 19 05:25 PM NSV Partners III LP 10% Owner Oct 09 '23 Sale 30.03 49,152 1,475,858 8,439,635 Oct 11 04:21 PM Subramaniam Somu Director Oct 09 '23 Sale 30.03 49,152 1,475,858 8,439,635 Oct 11 04:18 PM Mohan Raju Chief Executive Officer Oct 05 '23 Option Exercise 8.04 30,000 241,200 1,542,911 Oct 06 07:16 PM Mohan Raju Chief Executive Officer Oct 05 '23 Sale 29.11 30,000 873,231 1,512,911 Oct 06 07:16 PM Krueger Christopher W Chief Business Officer Oct 03 '23 Option Exercise 8.04 15,000 120,600 291,548 Oct 04 07:33 PM Krueger Christopher W Chief Business Officer Oct 03 '23 Sale 29.98 15,000 449,699 276,548 Oct 04 07:33 PM Nuss John Chief Scientific Officer Oct 03 '23 Option Exercise 3.35 10,000 33,542 254,815 Oct 04 07:26 PM Nuss John Chief Scientific Officer Oct 03 '23 Sale 29.99 10,000 299,933 244,815 Oct 04 07:26 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
